GT200200143A - Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales - Google Patents

Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales

Info

Publication number
GT200200143A
GT200200143A GT200200143A GT200200143A GT200200143A GT 200200143 A GT200200143 A GT 200200143A GT 200200143 A GT200200143 A GT 200200143A GT 200200143 A GT200200143 A GT 200200143A GT 200200143 A GT200200143 A GT 200200143A
Authority
GT
Guatemala
Prior art keywords
spinal
brain
receiver
treatment
neuronal injuries
Prior art date
Application number
GT200200143A
Other languages
English (en)
Inventor
Torsten Hoffmann
Alan John Nimmo
Andrew Sleight
Pierre Vankan
Robert Vink
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of GT200200143A publication Critical patent/GT200200143A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE UN ANTAGONISTA DEL RECEPTOR NK1 DE FORMULA GENERAL (I) EN DONDE R,R1,R2,R2', R3,R4,N,X, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS ACTUAN EN EL RECEPTOR NK1 QUE SE ENCUENTRA AMPLIAMENTE DISTRIBUIDO POR TODO EL SISTEMA NERVIOSO Y ESPECIALMENTE EN EL CEREBRO Y GANGLIOS ESPINALES Y SE CREE QUE ESTE RECEPTOR ESTA IMPLICADO EN LA REGULACION DE VARIOS PROCESOS Y ACCIONES A NIVEL PERIFERICO Y CENTRAL POR LO QUE SON UTILES EN LESIONES CEREBRALES, ESPINALES O NEURONALES.
GT200200143A 2001-07-10 2002-07-09 Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales GT200200143A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01116812 2001-07-10

Publications (1)

Publication Number Publication Date
GT200200143A true GT200200143A (es) 2002-11-11

Family

ID=8178001

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200143A GT200200143A (es) 2001-07-10 2002-07-09 Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales

Country Status (24)

Country Link
US (3) US20030083345A1 (es)
EP (2) EP1406618A2 (es)
JP (1) JP2004536119A (es)
KR (1) KR100589106B1 (es)
CN (1) CN100346789C (es)
AR (1) AR037008A1 (es)
AU (1) AU2002328837B2 (es)
BR (1) BR0210893A (es)
CA (1) CA2451566C (es)
GT (1) GT200200143A (es)
HK (1) HK1068266A1 (es)
HR (1) HRP20031071A2 (es)
HU (1) HUP0401210A3 (es)
IL (1) IL159350A0 (es)
MX (1) MXPA04000278A (es)
NO (1) NO332847B1 (es)
NZ (1) NZ530107A (es)
PA (1) PA8549901A1 (es)
PE (1) PE20030238A1 (es)
PL (1) PL211246B1 (es)
RU (1) RU2304435C2 (es)
UY (1) UY27374A1 (es)
WO (1) WO2003006016A2 (es)
ZA (1) ZA200400138B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50932B (sr) * 2000-07-14 2010-08-31 F. Hoffmann-La Roche Ag. N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora
NZ544244A (en) * 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
JP4580426B2 (ja) 2004-07-06 2010-11-10 エフ．ホフマン−ラ ロシュ アーゲー Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2601935C (en) * 2005-02-22 2013-04-09 F. Hoffmann-La Roche Ag Nk1 antagonists
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
PL1863767T3 (pl) * 2005-03-23 2009-08-31 Helsinn Healthcare Sa Metabolity antagonistów NK-1 do leczenia wymiotów
ES2439736T3 (es) 2005-11-08 2014-01-24 Vertex Pharmaceuticals Incorporated Moduladores heterocíclicos de transportadores de casete de unión a ATP
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DE102007018151A1 (de) * 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
AU2008278273A1 (en) * 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
CN101910156B (zh) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
CA2989620C (en) 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2271622B1 (en) 2008-02-28 2017-10-04 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR Modulators
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
DK3150198T3 (da) 2010-04-07 2021-11-01 Vertex Pharma Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
US20160129007A1 (en) * 2013-07-02 2016-05-12 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV
CA2914515C (en) * 2013-07-02 2018-12-11 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-i
KR101903713B1 (ko) * 2013-07-02 2018-10-04 유스트랄리스 파마슈티칼스 리미티드 (트레이딩 애즈 프레스수라 뉴로) 만성 외상성 뇌병증-ii를 예방 및/또는 치료하는 방법
KR20160078997A (ko) 2013-11-08 2016-07-05 깃세이 야쿠힌 고교 가부시키가이샤 카복시메틸피페리딘 유도체
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
JP6494757B2 (ja) 2014-11-18 2019-04-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ハイスループット試験高速液体クロマトグラフィーを行うプロセス
CN111741755B (zh) * 2018-02-02 2024-04-16 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） 肠胃外制剂及其用途
KR101970099B1 (ko) * 2018-02-07 2019-04-17 한국과학기술연구원 척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
US20230124548A1 (en) * 2019-08-23 2023-04-20 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Therapeutic Methods And Uses Thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5607947A (en) * 1995-02-21 1997-03-04 Eli Lilly And Company Pyrrolidinyl tachykinin receptor antagonists
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
CA2291734A1 (en) * 1997-06-27 1999-01-07 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
DK1157005T3 (da) * 1999-02-24 2005-02-14 Hoffmann La Roche 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
ATE496032T1 (de) * 1999-02-24 2011-02-15 Hoffmann La Roche 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
DE60006340T2 (de) * 1999-11-29 2004-09-09 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment

Also Published As

Publication number Publication date
HRP20031071A2 (en) 2004-06-30
CA2451566A1 (en) 2003-01-23
HUP0401210A2 (hu) 2004-10-28
NO332847B1 (no) 2013-01-21
MXPA04000278A (es) 2004-05-04
US20110053954A1 (en) 2011-03-03
RU2304435C2 (ru) 2007-08-20
NZ530107A (en) 2006-01-27
US20030083345A1 (en) 2003-05-01
EP1621195A2 (en) 2006-02-01
UY27374A1 (es) 2003-03-31
EP1621195A3 (en) 2010-01-06
WO2003006016A2 (en) 2003-01-23
PE20030238A1 (es) 2003-03-19
EP1406618A2 (en) 2004-04-14
WO2003006016A3 (en) 2003-07-31
US20060247240A1 (en) 2006-11-02
PL369535A1 (en) 2005-05-02
JP2004536119A (ja) 2004-12-02
BR0210893A (pt) 2004-06-22
PA8549901A1 (es) 2003-01-24
RU2004102397A (ru) 2005-04-20
ZA200400138B (en) 2005-06-29
CN1523988A (zh) 2004-08-25
KR100589106B1 (ko) 2006-06-14
HUP0401210A3 (en) 2011-07-28
PL211246B1 (pl) 2012-04-30
AR037008A1 (es) 2004-10-20
CN100346789C (zh) 2007-11-07
IL159350A0 (en) 2004-06-01
HK1068266A1 (en) 2005-04-29
KR20040029362A (ko) 2004-04-06
AU2002328837B2 (en) 2005-05-05
CA2451566C (en) 2013-09-10
NO20040057L (no) 2004-01-07

Similar Documents

Publication Publication Date Title
GT200200143A (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales o neuronales
GT200100160A (es) Derivados 4-fenil-piridina.
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
DOP2009000126A (es) Antagonistas de receptor de orexina de diazepan sustituído
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
UY27258A1 (es) Derivados de dihidro-benzo b 1, 4 diazepin-2-ona como antagonistas ii mglur2
DE69416869D1 (de) Diazabicyclische neurokinin antagonisten
BR0213208A (pt) Compostos de tetraidro- e hexaidro-carbazóis de arilsulfonila substituìda, suas composições e usos
HN2009001067A (es) Antagonistas de receptor de orexina de diazepan sustituido
ES2119124T3 (es) Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso.
MX9302888A (es) 1,2,3,4-tetrahidroisoquinolinas substituidas con propiedades antagonistas del receptor de angiotensina ii.
PA8543201A1 (es) DERIVADOS DE DIHIDRO-BENZO [B] [1,4]-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGluR2
PA8556901A1 (es) Nuevos derivados de piperazina
CY1106560T1 (el) Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων
AR031200A1 (es) Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR028705A1 (es) Bis-arilsulfonas
GT200200216A (es) Derivados del 3-azabiciclo [3.1.0] hexano
EA200301037A1 (ru) Производные имидазопиримидина в качестве лигандов для гамк рецепторов
AR031199A1 (es) Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
PA8575001A1 (es) Fluorobenzamidas como inhibidores de maob
ES2161377T3 (es) Derivados de octahidro-pirrolo(1,2-a)-pirazina 2,7-sustituidos.
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
IL158828A0 (en) Novel heteroaryl derivatives, their preparation and use
ES2156889T3 (es) Compuestos biciclicos antagonistas de receptores de aminoacidos excitativos.
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung